Enhancing the activation of T cells through anti-CD3/CD28 magnetic beads by adjusting the antibody ratio.

Autor: Chen Y; School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing, China., Zhao R; Beijing Scipromed Biotech Co., Ltd., Beijing, China., Fan Q; School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing, China., Liu M; Beijing Scipromed Biotech Co., Ltd., Beijing, China., Huang Y; Beijing Scipromed Biotech Co., Ltd., Beijing, China., Shi G; School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing, China.
Jazyk: angličtina
Zdroj: IUBMB life [IUBMB Life] 2024 Dec; Vol. 76 (12), pp. 1175-1185. Date of Electronic Publication: 2024 Jul 24.
DOI: 10.1002/iub.2898
Abstrakt: The utilization of anti-CD3/CD28 magnetic beads for T cell expansion in vitro has been investigated for adoptive cell transfer therapy. However, the impact of the CD3/CD28 antibody ratio on T cell differentiation and function remains incompletely elucidated. This study seeks to address this knowledge gap. To begin with, CD3 antibodies with a relatively low avidity for Jurkat cells (Kd = 13.55 nM) and CD28 antibodies with a relatively high avidity (Kd = 5.79 nM) were prepared. Afterwards, anti-CD3/CD28 antibodies with different mass ratios were attached to magnetic beads to examine the impacts of different antibody ratios on T cell capture, and proliferation. The research demonstrated that the most significant expansion of T cells was stimulated by the anti-CD3/CD28 magnetic beads with a mass ratio of 2:1 for CD3 antibodies and CD28 antibodies. Moreover, CD25 and PD1 expression of expanded T cells increased and then decreased, with lower CD25 and PD1 expression in the later stages of expansion indicating that T cells were not depleted. These T cells, which are massively expanded in vitro and have excellent expansion potential, can be infused back into the patient to treat tumor patients. This study shows that altering the ratio of anti-CD3/CD28 antibodies can control the strength of T cell stimulation, thereby leading to the improvement of T cell activation. This discovery can be utilized as a guide for the creation of other T cell stimulation approaches, which is beneficial for the further development of tumor immunotherapy technology.
(© 2024 International Union of Biochemistry and Molecular Biology.)
Databáze: MEDLINE
Externí odkaz: